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Clinical relevance of nontuberculous mycobacteria 
(NTM) isolated from 180 chronically ill patients and 385 
healthy controls in Zambia was evaluated to examine the 
contribution of these isolates to tuberculosis (TB)–like dis-
ease. The proportion of NTM-positive sputum samples was 
signiﬁ  cantly higher in the patient group than in controls; 11% 
and 6%, respectively (p<0.05). NTM-associated lung dis-
ease was diagnosed for 1 patient, and a probable diagnosis 
was made for 3 patients. NTM-positive patients and controls 
were more likely to report vomiting and diarrhea and were 
more frequently underweight than the NTM-negative pa-
tients and controls. Chest radiographs of NTM-positive pa-
tients showed deviations consistent with TB more frequently 
than those of controls. The most frequently isolated NTM 
was Mycobacterium avium complex. Multiple, not previous-
ly identiﬁ  ed mycobacteria (55 of 171 NTM) were isolated 
from both groups. NTM probably play an important role in 
the etiology of TB-like diseases in Zambia.
T
uberculosis (TB) is a problem of enormous dimen-
sions in Africa, and Mycobacterium tuberculosis is the 
most important causative agent. However, in industrialized 
countries, nontuberculous mycobacteria (NTM) also play 
a key role in etiology of TB-like syndromes. In Africa, the 
contribution of NTM to such disease has been examined on 
a small scale only (1–6).
Zambia is a country with historically high prevalence 
rates of TB. Patients with acid-fast bacilli (AFB)–positive 
sputum, or those with chest radiographic ﬁ  ndings sugges-
tive of active TB, who do not respond to general antimi-
crobial drugs, are generally presumed to have pulmonary 
TB. In general, these patients are treated empirically for 6 
months with a combination of drugs recommended by the 
World Health Organization. However, several TB-like syn-
dromes in Africa could be caused by NTM. Thus, inconclu-
sive diagnosis of pulmonary TB would lead to overdiagno-
sis of TB and in some cases, to inappropriate treatment for 
NTM infections.
When NTM are isolated from a usually sterile site (e.g., 
blood, bone marrow, lymph nodes, synovial ﬂ  uid), diagno-
sis of true disease is generally straightforward. However, 
when NTM are isolated from nonsterile sources, such as 
sputum or bronchoalveolar lavage samples, the diagnosis is 
less deﬁ  nitive, especially when the colony numbers are low 
or NTM are isolated from only 1 cultured specimen. There-
fore, it is a challenge to differentiate true NTM lung disease 
from contamination and colonization. Thus, ﬁ  nding AFB 
by microscopy of respiratory specimens or by culture may 
pose a diagnostic problem for the clinician. In 1997, the 
American Thoracic Society (ATS), published useful crite-
ria for determining the clinical relevance of NTM isolates 
(7). In 2007, the ATS guidelines were revised to include 
more lenient diagnostic criteria (8). Clinical criteria include 
a symptomatic patient with pulmonary symptoms, nodular 
or cavitary opacities on chest radiographs, or a high-res-
olution computed tomography scan that shows multifocal 
bronchiectasis with multiple small nodules. In addition, 
the microbiologic criteria comprise positive culture results 
from >2 separate sputum samples, or positive culture re-
sults from >1 bronchial wash or lavage, or a lung biopsy 
specimen with mycobacterial histopathologic features 
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(granulomatous inﬂ  ammation or AFB) and positive culture 
for NTM, or lung biopsy specimen showing mycobacterial 
histopathologic features and >1 sputum or bronchial wash-
ing culture positive for NTM.
In a pilot study performed in 3 hospitals in Zambia 
in 2001, high rates of NTM culture–positive sputum sam-
ples were obtained (P.C.A.M. Buijtels et al., unpub. data). 
Therefore, we studied the clinical relevance of and risk 
factors for isolation of NTM from HIV-positive and HIV-
negative patients with chronic productive cough and from 
randomly selected community controls in Zambia.
Materials and Methods
The study was conducted in St. Francis Hospital in 
the district of Katete in Zambia from August 2002 through 
March 2003. Informed consent was obtained from all pa-
tients and controls before enrollment. The study was re-
viewed and approved by the research ethics committee of 
the University of Zambia, the Central Board of Health, and 
the Ministry of Health in Zambia. 
The study population was composed of adults (>15 
years of age) with chronic (deﬁ  ned as >2 weeks) signs and 
symptoms and a productive cough who were admitted to 
the department of internal medicine at the hospital. Most 
(96%) of the included patients had respiratory tract symp-
toms. The other 4% of the patients had skin infections/ab-
scesses or lymphadenopathy.
For each eligible patient who consented to participate 
in the study, 2 healthy community controls were recruited 
randomly from the neighboring community. These controls 
were not matched for age or other characteristics of the pa-
tients. Nested within this case–control study, the charac-
teristics of NTM-positive and NTM-negative persons were 
analyzed separately.
At the time of enrollment, patients and controls were 
interviewed in their own language, and their medical re-
cords were reviewed by using a standard form. A detailed 
physical examination was conducted. Chest radiographs 
were evaluated in a blinded manner in the Netherlands 
without any additional clinical information. Radiographs 
were scored for mediastinal adenopathy, cavitation, pleural 
and pericardial ﬂ  uid, miliary pathologic changes, alveo-
lar inﬁ  ltration, interstitial pathologic changes, other lung 
pathologic changes, or no pathologic changes. Results of 
the scoring system were chest radiographs with no patho-
logic changes, pathologic changes not suggestive of TB, and 
pathologic changes consistent with TB. Over 3 consecutive 
days, sputum was collected from patients with a productive 
cough. Controls were asked to gargle with normal saline if 
they could not produce sputum. The ﬁ  rst 2 sputum samples 
or gargle specimens were cultured for mycobacteria, and a 
third sample was stored at –20°C until used.
Laboratory Methods
Sputum or gargle specimens were divided into 2 equal 
parts: half was decontaminated with N-acetyl-L-cysteine–
NaOH and half was decontaminated by using 6% sulfuric 
acid to compare these decontamination procedures for cul-
ture of mycobacteria (9). Specimens were cultured in My-
cobacteria Growth Indicator Tubes (Becton Dickinson Mi-
crobiology Systems, Cockeysville, MD, USA) according 
to the manufacturer’s instructions and guidelines reported 
by Master (10).  Mycobacterium isolates were identiﬁ  ed 
by using the Accuprobe culture conﬁ  rmation test for the 
M. tuberculosis complex (Accuprobe; bioMérieux, Marcy 
l’Etoile, France) or by 16S rRNA gene sequencing (11). 
Serologic testing for HIV was performed by using a quali-
tative immunoassay (Determine HIV-1/2; Abbott Labora-
tories, Abbott Park, IL, USA) and the Vidas HIV DUO as-
say (bioMérieux).
Data Analysis
Data were entered into SPSS version 6 software (SPSS 
Inc., Chicago, IL, USA) and analyzed by using STATA 
version 8.0 (StataCorp., College Station, TX, USA). Stu-
dent t-tests were used to assess different means between 
groups; proportions were compared by using χ2 tests. Uni-
variate odds ratios with 95% conﬁ  dence intervals were cal-
culated to assess associations of potential risk factors for 
NTM positivity. A stepwise backward regression approach 
was used for multivariate analysis.
Body mass index (BMI) was calculated as weight in 
kilograms divided by squared height in meters. Under-
weight was deﬁ  ned as a BMI <18.
Clinical Diagnosis of NTM Lung Disease
NTM lung disease was diagnosed if patients had re-
spiratory symptoms, abnormal chest radiographic results 
suggestive of Mycobacterium infection, and 2 positive spu-
tum cultures with the same NTM. Patients or controls with 
positive NTM cultures who did not meet these criteria were 
considered colonized.
Results
From August 2002 through February 2003, 180 pa-
tients and 385 controls were enrolled in the study. Two 
sputum samples were cultured from 154 patients and 383 
controls, and from 1 sample of the remaining participants. 
The median age of the patients and controls was 35 years 
(range 16–80 years) and 30 years (range 15–78 years), re-
spectively. Female participants represented 55% (99/180) 
of the patient group and 69% (265/385) of the control 
group. A total of 128 (71%) of the patients were HIV posi-
tive, and 87 (23%) of the controls were HIV positive. Sta-
tistically signiﬁ  cant differences in age, sex, and HIV status 
were observed between patients and controls.
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Culture Results for Patients
Of 180 patients, 60 (33%) had only M. tuberculosis 
isolates in their sputum samples, 12 (7%) had M. tuber-
culosis and NTM, and 19 (11%) had only NTM (Table 1). 
Microscopic results of Ziehl-Neelsen–stained smears of 
sputum samples were positive in 46 (67%) of 69 patients 
with M. tuberculosis isolates and in 1 patient with an NTM-
positive culture.
Of the 31 NTM-positive patients, 29 had 2 consecu-
tive sputum samples subjected to culture. In 22 of the 29 
patients, only 1 of 2 cultures was positive. Four NTM-
positive patients had 2 positive NTM cultures; 1 of these 
patients had pulmonary disease. M. intracellulare was iso-
lated twice from 2 of these 4 patients, M. avium was iso-
lated from both samples from 1 patient, and NTM of 2 spe-
cies and M. tuberculosis was isolated from 1 patient. One 
of 2 sputum cultures from 3 other NTM-positive patients 
contained mycobacteria that could not be identiﬁ  ed. Two of 
these 3 patients had M. intracellulare in 1 sputum sample; 
M. porcinum was isolated from 1 patient.
Case Reports for Patients with Suspected 
NTM Disease
Characteristics of the 4 patients with NTM isolates in 
both sputum samples and of the 3 NTM-positive patients 
from whom 1 of the 2 sputum samples contained mycobac-
teria that could not be identiﬁ  ed are shown in Table 2. For 
3 patients (1, 2, and 4), NTM-associated disease was sus-
pected because of the combination of symptoms, positive 
cultures, and pathologic changes consistent with TB seen 
on chest radiographs. However, only 1 patient (patient 4) 
fulﬁ  lled the ATS criteria for NTM lung disease. M. intrac-
ellulare was isolated from all 3 of these patients.
The ﬁ  rst patient (patient 4) was a 32-year-old HIV-
positive man who reported having had a productive cough 
with hemoptysis for 17 weeks. He also was vomiting and 
had diarrhea. His BMI was 15. He had been treated for 
TB. Results of a chest radiograph were consistent with TB 
and showed alveolar inﬁ  ltration and interstitial pathologic 
changes. His condition did improve after treatment with an-
timicrobial drugs (chloramphenicol and tetracycline), and 
he was again given treatment for TB. Mycobacteria were 
cultured from 2 sputum samples and identiﬁ  ed as M. intra-
cellulare. The patient died 5 weeks later.
The second patient (patient 1), who had M. intracel-
lulare pulmonary disease, was a 55-year-old HIV-positive 
man. He was admitted because of a productive cough with 
hemoptysis for 17 weeks. Diarrhea was also reported; his 
BMI was 17. He had been receiving treatment for TB for 4 
months. Sputum obtained before treatment was AFB nega-
tive. Radiographic investigation of the chest showed cavi-
ties and alveolar consolidation. No improvement was seen 
after he was treated with antimicrobial drugs (chloram-
phenicol, amoxicillin, gentamicin, and metronidazole). 
Sputum was examined again and was smear positive for 
AFB. The ﬁ  rst sputum culture showed M. intracellulare. In 
the second sputum culture, the isolated mycobacteria could 
not be identiﬁ  ed because of logistic reasons. The patient 
died 3 weeks later.
The third patient (patient 2), who had M. intracellu-
lare pulmonary disease, was a 45-year-old HIV-positive 
woman who had had respiratory signs and symptoms for 
>1 year. She was known to have asthma. Physical exami-
nation found enlarged submandibular, supraclavicular, 
and axillary lymph nodes. Her BMI was 20. Alveolar in-
ﬁ  ltration was seen on a chest radiograph. Treatment with 
chloramphenicol was started. Culture of the ﬁ  rst sputum 
sample showed mycobacteria that could not be identiﬁ  ed; 
the second sputum showed M. intracellulare. Three days 
after admission, the patient was taken home by her family 
and was lost to follow-up.
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Table 1. Culture results for 180 hospitalized chronically ill patients and 385 controls, Zambia, August 2002–March 2003* 
Results Patients Controls
Culture exclusively Mycobacterium tuberculosis, no. (%)  60 (33)  2 (0.5) 
Culture M. tuberculosis and NTM, no. (%)  12 (7)  1 (0.3) 
Culture exclusively NTM,† no. (%)  19 (11)  61 (16) 
Culture NTM,‡ no. (%)  31 (17)  62 (16) 
2 sputum or gargle samples cultured  154 383
2 sputum or gargle samples cultured from NTM-positive person  29 of 31 NTM-positive 
patients
62 of 62 NTM-positive 
controls
1 NTM-positive culture in NTM-positive person with 2 samples cultured  22 of 29 NTM-positive 
patients
61 of 62 NTM-positive 
controls
1 NTM-positive cultures in NTM-positive person with 2 samples cultured  4 of 29 NTM-positive 
patients
1 of 62 NTM-positive 
controls
2 NTM-positive cultures in persons with 2 samples cultured§  4 of 154 patients with 2 
samples cultured 
1 of 383 controls with 2 
samples cultured 
*NTM, nontuberculous mycobacteria. 
†Proportion of patients with exclusively NTM was comparable with controls (p = 0.2). 
‡NTM isolated with or without M. tuberculosis.
§Significantly more patients than controls had 2 sputum or gargle cultures positive for NTM (p<0.05). Nontuberculous Mycobacteria, Zambia
Culture Results for Controls
M. tuberculosis was cultured from sputum or gargle 
specimens from 3 (0.8%) of the 385 controls; in 1 of these 3 
controls, NTM and M. tuberculosis were isolated (Table 1). 
In 61 (16%) controls, only NTM were isolated; this num-
ber was comparable with the proportion of patients among 
whom only NTM were isolated (11%; p = 0.2). In 61 of 62 
NTM-positive controls, only 1 sputum or gargle specimen 
was culture positive for NTM. In 1 control, who was HIV 
negative, 2 mycobacteria, M. porcinum and an unknown 
Mycobacterium sp., were isolated. No chest radiographs 
suggestive of TB were observed for any of the controls.
From 383 controls, 2 sputum or gargle samples were 
cultured for Mycobacterium spp. Signiﬁ  cantly fewer con-
trols (1/383) than patients (4/154) had 2 sputum or gargle 
cultures positive for NTM (p<0.05).
Mycobacterium spp. Isolated
To compare the inﬂ   uence of the decontamination 
method on the yield of mycobacteria, we divided sputum 
or gargle samples from all patients and controls into 2 equal 
parts before decontamination (9). A total of 635 sputum 
samples were cultured from 180 patients, and 1,532 sputum 
or gargle samples were cultured from 385 controls. The re-
sults of the cultures are shown in Table 3. The number of 
NTM (72) isolated from 635 sputum samples of patients 
was signiﬁ  cantly higher than the number of NTM (99) iso-
lated from 1,532 sputum or gargle samples from controls 
(11% and 6%, respectively, (p<0.001).
Mycobacteria were isolated from 273 (43%) of 635 
sputum samples from patients; M.  tuberculosis isolates 
were found in 201 (74%) of the 273 positive sputum speci-
mens, and NTM were found in 72 (26%). The most fre-
quently isolated NTM was M. intracellulare, which was 
found in 12 specimens.
Mycobacteria were isolated from 104 (6.8%) of 1,532 
sputum or gargle samples cultured from the controls. M. 
tuberculosis was found in 5 (4.8%) of the 104 positive cul-
tures, and NTM were found in 99 (95%). The predominant 
NTM isolated from the controls were M. avium (5 speci-
mens), M. goodii (4 specimens), and M. peregrinum (4 
specimens).
A total of 55 (32%) of 171 NTM isolated from patients 
and controls were not identiﬁ  ed because their 16S rDNA 
sequences were absent in the BLAST (National Center for 
Biotechnology Information, Bethesda, MD, USA, www.
ncbi.nlm.nih.gov) database. These 55 NTM species were 
closely related to various Mycobacterium spp. such as M. 
intracellulare, M. malmoense, M. fortuitum, M. smegmatis, 
and M. terrae.
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Table 2. Data for 4 patients with NTM in 2 consecutive sputum samples and 3 NTM-positive patients from whom 1 of 2 sputum 
samples contained mycobacteria that could not be identified, Zambia, August 2002–March 2003* 
Patient
no.
Isolate from first 
sputum sample 
Isolate from 
second sputum 
sample
Ziehl-
Neelsen
staining Sex Age, y 
HIV
status
Temp,
°C
Duration,
wk 
Chest
radiograph 
result  Died BMI
1† Mycobacterium 
intracellulare
AFB not 
identified
1+ M 55 + 34.6 17 Suspected TB  Yes  17
2† AFB not 
identified
M. intracellulare – F 45 + 36.1 487 Suspected TB  No 20
3 M. intracellulare M. intracellulare – M 43 + 36.3 3 No pathologic 
changes
No 19
4† M. intracellulare M. intracellulare – M 32 + 36.8 17 Suspected TB  Yes  15
5 AFB not
identified
M. porcinum – F 50 – 36.6 8 No suspected 
TB
No 21
6 M. avium M. avium – M 33 + 37.4 17 No radiograph  No 16
7 M. avium M. peregrinum,
M. tuberculosis
– F 24 + 35.0 13 No pathologic 
changes
Yes NK 
*NTM, nontuberculous mycobacteria; Temp, temperature at time of enrollment; Duration, duration of symptoms from time of coming to the hospital to 
enrollment in the study; BMI, body mass index; AFB, acid-fast bacilli; TB, tuberculosis; NK, not known. All patients had respiratory symptoms. 
†Patients assumed to have pulmonary NTM disease. 
Table 3. Results from cultures of sputum samples taken from 
hospitalized chronically ill patients and controls, Zambia, August 
2002–March 2003 
Result
Patients,
no. (%) 
Controls,
no. (%) 
Negative 362 (57)  1,428 (93) 
Mycobacterium tuberculosis 201 (32)  5 (0.3) 
M. avium complex  15 (2)  5 (0.3) 
 M.  intracellulare 12 (2)  0
 M.  avium 3 (0.5)  5 (0.3) 
M. gordonae 4 (0.6)  0
M. peregrinum 2 (0.3)  4 (0.3) 
M. goodie 1 (0.2)  4 (0.3) 
M. porcinum 1 (0.2)  3 (0.2) 
M. lentiflavum 1 (0.2)  0
Unknown Mycobacterium spp.  13 (2)  42 (3) 
Other Mycobacterium spp.*  3 (0.5)  7 (0.5) 
Unidentified acid-fact bacilli  32 (5)  34 (2) 
Total no. sputum samples  635 1,532
*Other Mycobacterium spp. in patients were M. fortuitum, M. neoaurum,
and M. simiae. Other Mycobacterium spp. in controls were M. fortuitum, M. 
asiaticum, M. aurum, and M. conspicuum.RESEARCH
Comparison of Persons with and without 
NTM in Sputum or Gargle Samples
The 93 patients and controls with NTM-positive cul-
tures had different clinical and radiographic features than 
the 472 patients and controls without NTM in sputum 
samples (Table 4). These persons were more likely to re-
port vomiting and diarrhea, were more often underweight 
(BMI<18), more often had general malaise, and their chest 
radiographs more frequently showed changes consistent 
with TB, such as consolidation and interstitial changes. 
HIV status and presence of M. tuberculosis in the sputum 
culture did not differ between the NTM-positive and NTM-
negative groups. There were no signiﬁ  cant differences be-
tween these groups in terms of age (mean 36.7 years vs. 
34.8 years; p = 0.2), sex, smoking habits, alcohol use, and 
previous treatment for TB (Table 5). The percentages of 
farmers and of persons in both groups who used unboiled 
milk were comparable. Moreover, NTM-positive persons 
used tap water more often than NTM-negative persons (p 
= 0.004). A subgroup analysis, restricted to patients with 
NTM and patients without NTM in sputum, yielded similar 
results (data not shown).
Independent risk factors for NTM culture–positive 
sputum were determined by using multivariate analysis. 
Two factors, underweight (BMI<18) and use of tap water, 
were independently associated with having an NTM-posi-
tive sputum culture (Table 6).
Discussion
The purposes of this study were to compare the preva-
lence of NTM in sputum between hospitalized chronically 
ill patients and community controls and to determine the 
clinical importance of isolation of NTM. The proportions 
of patients and controls with positive sputum or gargle cul-
tures for NTM were comparable (11% and 15%, respec-
tively). However, the proportion of NTM-positive sputum 
samples was higher for patients than for controls (11% and 
6%, respectively). This ﬁ   nding suggests that persistent 
NTM are associated with chronic illness in these patients. It 
is not known whether culture results were inﬂ  uenced by the 
method of obtaining specimens. A gargle specimen con-
tains ﬂ  ora of the oropharyngeal mucosa, whereas a sputum 
sample contains ﬂ  ora of the lower airways. In the patient 
group, more persons were capable of producing sputum, 
which may have inﬂ  uenced the yield of positive NTM-
positive cultures.
NTM lung disease was deﬁ  nitively diagnosed for 1 pa-
tient and probable diagnosis was made for 3 patients (nos. 
1, 2, and 4; Table 2). M. intracellulare was isolated from 
the sputum samples of these HIV-positive patients. These 
patients had respiratory symptoms, and chest radiographs 
showed pathologic changes compatible with TB. Unfortu-
nately, in 2 of these patients, 1 of 2 sputum samples with 
mycobacteria could not be identiﬁ  ed because of contamina-
tion and reculture problems.
The combination of symptoms, positive cultures, and 
pathologic changes seen on chest radiographs are charac-
teristics of NTM infection and suggestive of NTM pulmo-
nary disease. However, the ATS criteria valid at the time 
of the study were not completely fulﬁ  lled because only 2 
sputum samples were cultured for mycobacteria on con-
secutive days, instead of the 3 samples recommended. 
Furthermore, 2 of these patients suspected of having NTM 
lung disease had been treated for TB. Because these spu-
tum samples were not tested with molecular ampliﬁ  cation 
techniques for multidrug-resistant M. tuberculosis, the pos-
sibility that they had multidrug-resistant TB could not be 
excluded (12,13). Conversely, performance of these nu-
cleic acid ampliﬁ  cation tests is generally good for clinical 
respiratory specimens that are AFB smear positive but less 
so for specimens that contain fewer organisms or are AFB 
negative. Moreover, because sputum specimens were not 
cultured on solid medium, it was not possible to count the 
number of colony-forming units to distinguish colonization 
and infection from disease.
Many risk factors for NTM have been identiﬁ  ed 
(14–16). In this study in a setting in Africa, HIV, sex, and 
age were not risk factors for NTM. The 2 risk factors for 
a positive NTM culture were being underweight and hav-
ing consumed tap water. NTM are natural inhabitants of 
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Table 4. Clinical data for samples obtained from NTM-positive and NTM-negative persons, Zambia, August 2002–March 2003* 
Characteristic NTM-positive samples NTM-negative samples  p value  All samples 
Persons, no. (%)  93 (16.5)  472 (83.5)  – 565
HIV positive, no. (%)  41 (45.6)  174 (38.5)  0.2 215 (39.7) 
Mycobacterium tuberculosis, no. (%) 13 (14.0)  62 (13.1)  0.8 75 (13.3) 
BMI, mean (SD)  20.2 (4.2)  20.8 (3.7)  0.2 20.7 (3.8) 
Underweight, no. (%)  26 (29.6)  92 (20.6)  0.06 118 (22.1) 
Vomited, no. (%)  8 (8.6)  18 (3.8)  0.04 26 (4.6) 
Diarrhea, no. (%)  12 (12.9)  11 (2.3)  <0.001 23 (4.7) 
Lymph nodes analyzed, no. (%)  21 (22.8)  146 (30.9)  0.1 167 (29.6) 
Chest radiograph compatible with TB but 
culture negative for M. tuberculosis, no. (%) 
5 (26.3)  28 (7.1)  0.003 33 (8.0) 
Died, no. (%)  9 (9.7)  26 (5.5)  0.1 35 (6.2) 
*NTM, nontuberculous mycobacteria; BMI, body mass index; TB, tuberculosis. Nontuberculous Mycobacteria, Zambia
municipal water systems and soil. A bioﬁ  lm may form in 
the water distribution system and be a source of replicating 
NTM (17). Consequently, availability of clean tap water 
may introduce a serious danger, in particular, to immu-
nosuppressed human populations. Therefore, tap water in 
Zambia should be tested for NTM.
In this study, patients and controls with NTM in spu-
tum or gargle samples more often had symptoms and signs 
of general malaise, including diarrhea, vomiting, and being 
underweight, and chest radiographs for these NTM-posi-
tive persons more often showed pathologic changes than 
did those for NTM culture-negative persons. These symp-
toms and signs may not be speciﬁ  c for NTM infection, but 
they may reﬂ  ect the patients’ poor health in general.
Differences in geographic distribution of NTM species 
have been reported (16,18,19). The most commonly en-
countered NTM from clinical specimens in industrialized 
countries are M. avium complex (MAC) and M. kansasii 
(20–24). Despite limited studies conducted in Africa, the 
distribution of NTM is not known. In our study, the most 
commonly isolated NTM in patients and controls was M. 
avium complex. However, 32% of NTM found in both 
groups in Zambia have not been identiﬁ  ed on a species 
level. This study indicates that the distribution of NTM 
in Africa may differ from that in Europe and the United 
States. NTM in Africa may have diverged from NTM in 
industrialized countries. This hypothesis could be tested by 
extensive DNA sequencing of semiconserved genes such 
as those for RNA polymerase B and 65-kD heat-shock 
protein. Unidentiﬁ  ed NTM colonize persons in Africa and 
can cause disease in some instances. The magnitude of this 
problem, in addition to the problem of TB, is unknown but 
deserves more attention.
Rates of NTM colonization and disease that have been 
reported vary in different areas. In North America and 
Europe, rates of colonization and disease in the general 
population range from ≈1–15/100,000 persons to 0.1–2
/100,000 persons, respectively (20–23,25–28). These rates 
are largely unknown for most countries in Africa. In South 
Africa, prevalence rates of NTM colonization of 1,400–
6,700/100,000 persons have been reported (29,30). In gold 
miners in South Africa, rates of infection were 101/100,000 
persons for NTM, 66/100,000 persons for M. kansasii, 
and 12/100,000 persons for M. scrofulaceum (31,32). Al-
though numbers of cases were small, the estimated rate 
of colonization in our study in the patient population was 
9% (14/154) and the rate of disease was ≈2% (3/154). Two 
sputum or gargle specimens were collected and cultured 
from 383 controls in our study. NTM were isolated from 
both specimens for 1 of 61 controls with >1 sample being 
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Table 5. Background characteristics of NTM-positive and NTM-negative persons, Zambia, August 2002–March 2003* 
Characteristic NTM positive, no. (%)  NTM negative, no. (%)  p value  All persons, no. (%) 
Persons 93 (16.5)  472 (83.7)  – 565
Female 61 (65.6)  303 (64.2)  0.8 364 (64.4) 
Age, y, mean (SD)  36.7 (13.1)  34.8 (14.6)  0.2 35.1 (14.4) 
Farmer  48 (51.6)  245 (51.9)  1.0 293 (51.9) 
Used tap water  23 (25.0)  62 (13.2)  0.004 85 (15.1) 
Used unboiled milk  15 (16.1)  62 (13.1)  0.4 77 (13.6) 
Smoker 5 (5.7)  41 (8.9)  0.3 46 (8.4) 
Used alcohol  9 (10.3)  51 (11.2)  0.8 60 (11.0) 
Hospitalized 31 (33.3)  149 (31.6)  0.7 180 (31.9) 
Previously treated for TB  9 (9.7)  28 (5.9)  0.2 37 (6.6) 
*NTM, nontuberculous mycobacteria; TB, tuberculosis. 
Table 6. Crude and adjusted risk factors for isolation of NTM from sputum samples, Zambia, August 2002–March 2003* 
Factor Univariate analysis, OR (95% CI)  Multivariate analysis, OR (95% CI)† 
Hospitalized 1.1 (0.7–1.7) NS
Age >25 y  1.3 (0.8–2.5)  NS
Sex (female)  1.1 (0.7–1.7)  NS
Underweight (BMI <18)  1.6 (1.0–2.7)  1.7 (1.0–2.9) 
Mycobacterium tuberculosis infection 1.1 (0.6–2.0) NS
Previous treatment for TB  1.7 (0.8–3.7)  NS
HIV positive  1.3 (0.8–2.1)  NS
Used tap water  2.2 (1.3–3.8)  2.0 (1.1–3.5) 
Used alcohol  0.9 (0.4–1.9)  NS
Smoker 0.6 (0.2–1.6) NS
Used unboiled milk  1.3 (0.7–2.3)  NS
Farmer 1.0 (0.6–1.5)  NS
Chest radiograph compatible with TB but culture negative 
for M. tuberculosis
4.7 (1.6–13.9)  NS
*NTM, nontuberculous mycobacteria; OR, odds ratio; CI, confidence interval; NS, not significant; BMI, body mass index; TB, tuberculosis. 
†Stepwise backward elimination. RESEARCH
culture positive for NTM. This control was not suspected 
of having NTM pulmonary disease. The estimated rate of 
colonization in the general population on the basis of this 
result is 16% (61/383).
NTM probably play a role in the etiology of TB-like 
disease in Zambia. More extended studies, in terms of du-
ration and size, will be needed to determine the true preva-
lence of NTM infection in Africa.
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